Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price ...

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

Esteve will license the ex-U.S. rights for up to ten years and will also be receiving an option to acquire the international ...